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ABSTRACT
This study describes the influence of hepatitis C
virus (HCV) and hepatitis G virus (HGV) co-
infection on CD4 cell count decline and plasma
human immunodeficiency virus (HIV) viral load
in HIV-infected patients during a 1-year period
following interruption of highly active anti-retro-
viral therapy (HAART) guided by CD4 count.
CD4 cell count decline and plasma HIV viral load
did not differ between HIV mono-infected pa-
tients and those patients co-infected with HCV
and HGV. HCV genotype 1 had no apparent
influence on the cellular and viral dynamics in
HIV-infected patients compared with other HCV
genotypes, although the unbalanced groups make
larger studies desirable.
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(HIV) who are receiving anti-retroviral therapy
remains controversial. Some reports have shown
that HCV co-infection has a negative effect on
CD4 cell re-population, and even influences
adversely clinical progression of HIV disease
and survival [1,2], while others have suggested
that HCV co-infection may have an adverse effect
only during the immediate period following the
initiation of highly active anti-retroviral therapy
(HAART), despite similar declines in HIV viral
load in HIV mono-infected and HCV co-infected
patients [3]. These differences might be explained
by differences in the selection criteria for patients
and the HCV genotype involved, as HCV geno-
type 1 has been reported to be associated with a
lower CD4 cell count and a more rapid progres-
sion of HIV disease in HIV co-infected patients
[4]. In contrast, it has been reported that HIV–
hepatitis G virus (HGV) co-infection is associated
with slower progression of disease [5] and a
lower risk of HIV viral load rebound in patients
who commence HAART [6]. The present study
investigated the influence of HIV–HCV and HIV–
HGV co-infection on the cellular and HIV dynam-
ics in patients who commence interruption of
anti-retroviral treatment.
In July 2003, the Viral Hepatitis and AIDS
Study Unit (Seville, Spain) began a study of
HAART interruption guided by CD4 cell count.
The selection criteria for the study were: (1) a
persistently undetectable plasma HIV viral load
(< 50 copies ⁄mL) for at least the preceding
12 months; (2) a CD4 cell count > 500 cells ⁄mm3
at the time of therapy interruption; and (3) a nadir
CD4 cell count ‡ 250 cells ⁄mm3. Of 45 HIV-infec-
ted patients who began the treatment interruption
programme before April 2004, 36 fulfilled these
criteria and gave written informed consent to
participate in the study. Clinical and immuno-
virological parameters were determined at base-
line and on a 4-weekly basis until week 52 after
discontinuation, at which time the study results
were analysed. The Ethical Committee of the
hospital approved the study.
Total CD4 cell count was determined in fresh
plasma samples by conventional flow cytometry,
and plasma HIV-1 RNA load was quantified by
PCR (HIV Monitor Test; Roche Molecular Sys-
tems, Basel, Switzerland) according to the manu-
facturer’s instructions. This assay has a detection
limit of 50 HIV-1 RNA copies ⁄mL. Plasma HCV
RNA was quantified by PCR (COBAS Amplicor;
Roche Diagnostics, Barcelona, Spain). Plasma
HGV RNA was extracted and reverse transcribed
with avian myeloblastosis virus reverse transcrip-
tase (AMV-RT) and random primers at 42C for
1 h. cDNA was used to amplify the HGV-5¢-UTR
(untranslated region) using outer primers A
(5¢-TGCAAGCCCCAGAAACCGACG-3¢) and B
(5¢-AGAGACATTGAAGGGCGACG-3¢). Nested
PCR was performed using inner primers C
(5¢-CAGGGTTGGTAGGTCGTAAATC-3¢) and D
(5¢-CCGTACGTGGGCGTCGTTGC-3¢). After 40
cycles of 94C for 20 s, 57C for 15 s and 72C
for 30 s, the amplified nested PCR products were
analysed by electrophoresis in agarose 1.5% w ⁄ v
gels containing ethidium bromide, followed by
visualisation under UV light.
Continuous variables were expressed as a
median (including interquartile range) and categ-
orical variables as the number of cases (percent-
age). Mann–Whitney U-tests were used to analyse
differences among different groups of patients,
i.e., CD4 cell counts and HIV plasma viral loads
between HIV mono-infected and HIV–HCV or
HIV–HGV co-infected patients at each time-point
of the follow-up. Statistical analyses were
performed using SPSS v. 12.0 (SPSS Inc., Chicago,
IL, USA).
Baseline characteristics of the 36 HIV-infected
patients were as follows: (1) HIV mono-infection
was present in 16 (44%; 12 males, four females)
patients, two of whom were injecting drug users,
with a median CD4 count of 995 (786–
1173) cells ⁄mm3, a median nadir CD4 count of
364 (329–475) cells ⁄mm3, and a median age of 41
(36–46) years; (2) HCV co-infection was present in
14 (39%; 11 males, three females) patients, nine of
whom were injecting drug users, with a median
CD4 count of 1177 (803–1385) cells ⁄mm3, a
median nadir CD4 count of 369 (340–
432) cells ⁄mm3, and a median age of 40 (39–
42) years; (3) six patients were co-infected by
genotype 1, but none was infected with HGV; and
(4) HGV co-infection was present in six (17%; all
males) patients, none of whom was an injecting
drug user or infected with HCV, with a median
CD4 count of 1051 (731–1407) cells ⁄mm3, a
median nadir CD4 count of 348 (326–
469) cells ⁄mm3, and a median age of 37 (27–
42) years. During the follow-up period, eight
patients resumed HAART at different time-
points: two following a CD4 cell decline to
< 350 cells ⁄mm3, one for thrombocytopenia and
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two as a result of self-decision among HIV mono-
infected patients; one for thrombocytopenia and
one as a result of self-decision among HCV co-
infected patients; and one as a result of self-
decision among HGV co-infected patients.
As shown in Fig. 1, neither the CD4 count
nor the plasma HIV viral load was significantly
different between HIV mono-infected and HCV
co-infected patients at any of the sampling time-
points during the follow-up period (p > 0.05 for
every time-point). In addition, the CD4 cell
count and plasma HIV viral load did not differ
significantly between HIV-infected patients who
were co-infected by HCV genotype 1 and those
who were co-infected by other HCV genotypes.
Neither were differences found between HIV
mono-infected and HCV genotype 1 co-infected
patients. CD4 cell count decline and plasma
HIV viral load rebound also did not differ
significantly between HGV co-infected and HIV
mono-infected patients at any time-point during
the follow-up period.
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Fig. 1. (A) CD4 cell count (cells ⁄
mm3) and (B) plasma HIV viral load
(log10 copies ⁄mL) in HIV mono-
infected (squares) and in HCV co-
infected (triangles) patients during
52 weeks of follow-up.
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HCV co-infection seemed to have no influence
over the CD4 cell decline or plasma HIV viral load
in HIV-infected patients undergoing HAART
interruption. On the other hand, the reported
benefit of HGV co-infection, probably caused by
HIV and HGV competitive replication, which may
influence the lower plasma HIV viral load and the
higher CD4 cell count found in patients receiving
HAART [6], was not found during treatment
discontinuation. This latter finding has to be
treatedwith caution, since the populations studied
were not balanced (six and 16 patients, respect-
ively), and larger studies are desirable.
In summary, neither HCV (including genotype
1) nor HGV co-infection had any influence on
CD4 cell count decline or plasma HIV viral load
rebound in HIV-infected patients undergoing
HAART interruption. However, larger numbers
of patients should be analysed to confirm these
results.
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ABSTRACT
Rapid, accurate and inexpensive methods are
essential to detect drug-resistant Mycobacterium
tuberculosis and allow timely application of effect-
ive treatment and precautions to prevent trans-
mission. The proportion method, the MTT and
Alamar Blue redox methods, and the D29 myco-
bacteriophage assay, were compared for their
ability to detect resistance to isoniazid and rif-
ampicin. When tested against a panel of known
M. tuberculosis strains, the redox methods and the
D29 assay showed good sensitivity and specificity
compared to the proportion method, suggesting
that they could be useful alternatives for identi-
fying multidrug resistance in M. tuberculosis.
Keywords Antibiotic resistance, D29 mycobacteri-
ophage, detection, drug susceptibility testing, Myco-
bacterium tuberculosis, redox methods
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